search
Back to results

12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat

Primary Purpose

Non-Alcoholic Fatty Liver Disease, Central Obesity

Status
Recruiting
Phase
Not Applicable
Locations
Hong Kong
Study Type
Interventional
Intervention
High-intensity Interval Training
Usual Care Control
Sponsored by
The University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Alcoholic Fatty Liver Disease focused on measuring Long-Term Low-Frequency High-Intensity Interval Training, Non-Alcoholic Fatty Liver Disease, Central Obesity, Body Adiposity, Liver Fat

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Cantonese, Mandarin or English speaking,
  2. Aged 18-60,
  3. Central obesity, defined as BMI ≥25 (obesity classification adopted by the Hong Kong Government) with waist circumference of ≥90 cm for men and ≥80 cm for women (abdominal obesity according to the International Diabetes Federation's Chinese ethnic-specific criterion),
  4. Willing to initiate lifestyle modification but not pharmacologic or surgical means for treating obesity.

Exclusion criteria:

  1. ≥150 minutes moderate-intensity exercise or ≥75 minutes vigorous exercise weekly,
  2. Regular HIIT (≥1 weekly) in the past six months,
  3. Medical history of cardiovascular disease, chronic pulmonary or kidney disease, heart failure, cancer, and liver disease except for NAFLD,
  4. Somatic conditions that limit exercise participation (e.g., limb loss),
  5. Impaired mobility due to chronic diseases (e.g., chronic arthritis/osteoarthritis, neurological, musculoskeletal and autoimmune diseases),
  6. Daily smoking habit,
  7. Excess alcohol consumption (daily ≥30 g of alcohol for men and ≥20 g for women) in the past six months
  8. Surgery, therapy or medication for obesity or weight loss in the past 6 months (e.g., gastric bypass, gastric band, sleeve gastrectomy, gastric reduction duodenal switch, and dietitian-prescribed dietary program).
  9. During the study period, subjects identified with major physical changes that would considerably affect their body composition and weight (e.g., anorexia nervosa, bulimia nervosa, and prolonged gastrointestinal and digestive disorders) will be excluded.

Sites / Locations

  • Li Ka Shing Faculty of Medicine, The University of Hong KongRecruiting
  • Li Ka Shing Faculty of Medicine, The University of Hong KongRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Usual Care Control

High-intensity Interval Training Group

Arm Description

Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend >70% of the classes.

HIIT will be prescribed once weekly under the supervision of certified athletics coaches for 12 months. HIIT training will be performed in a small group setting (4-8 participants each group) in laboratories. In each session, subjects will run for four 4-minute intervals at 85%-95% of the peak heart rate (HRpeak) with a 3-minute active recovery at 50%-70% of the HRpeak between each interval. A 5-minute jog at an intensity of 70% of the HRpeak will be included for warm-up and cool-down before and after, respectively. Subjects will be asked to attend >70% of the classes.

Outcomes

Primary Outcome Measures

Liver Fat
Intrahepatic triglycerides will be examined by 1H-MR spectroscopy in a 3×3×3 cm voxel using a 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. NAFLD will be defined as >5% intrahepatic triglycerides assessed by 1H-MR spectroscopy.
Body Adiposity
Total body fat mass will be determined using a full body dual-energy X-ray absorptiometry (DXA) scanner (Explorer S/N 91075, Hologic Inc., Waltham, USA). A trained technician will operate the DXA machine, position the subjects and analyze the results. The typical coefficients of variation of the DXA scanner for each body compartment from duplicate analyses are 0.4% for lean mass, 1.4% for fat mass and 1.0% for bone mass
Liver Fat
Intrahepatic triglycerides will be examined by 1H-MR spectroscopy in a 3×3×3 cm voxel using a 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. NAFLD will be defined as >5% intrahepatic triglycerides assessed by 1H-MR spectroscopy.
Body Adiposity
Total body fat mass will be determined using a full body dual-energy X-ray absorptiometry (DXA) scanner (Explorer S/N 91075, Hologic Inc., Waltham, USA). A trained technician will operate the DXA machine, position the subjects and analyze the results. The typical coefficients of variation of the DXA scanner for each body compartment from duplicate analyses are 0.4% for lean mass, 1.4% for fat mass and 1.0% for bone mass

Secondary Outcome Measures

Visceral Adiposity
Abdominal visceral fat will be measured using a three-point Dixon sequence using a 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. The abdominal visceral fat between the thoracic diaphragm and the upper bORDER of the first sacral vertebra will be manually marked on each MRI transverse image to calculate the volume of abdominal visceral fat.
Subcutaneous Adiposity
Subcutaneous fat will be measured using a three-point Dixon sequence using 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. The abdominal subcutaneous fat between the thoracic diaphragm and the upper border of the first sacral vertebra will be manually marked on each MRI transverse
Body Mass Index
A calibrated electronic digital weighing scale (UC321, A&D Medical) with a capacity from 0.05kg to 150kg (± 0.05kg accuracy) will be used to weigh the subjects. A stadiometer (Holtain Ltd., UK) with 200 cm limit and ± 0.01 cm accuracy will be used to measure body height. The BMI will be calculated from the body weight and height.
Waist Circumference
Waist circumference will be measured on bare skin midway between the lowest rib and the superior border of the iliac crest using an inelastic measuring tape to the nearest 0.1 cm. Measurement will be performed at the end of normal expiration.
Hip Circumference
Hip circumference will be be taken on bare skin around the widest portion of the buttocks using an inelastic measuring tape to the nearest 0.1 cm and the tape should be placed parallel to the floor.
VO2max
VO2max test will be conducted using a calibrated motor-driven treadmill (LE500C, Jaeger, Germany) by continuous metabolic VO2 measurement using a Cosmed K5 portable telemetric gas analysis system. The test will be performed using a ramp protocol where the speed will be constant and the incline will be increased by 2% every second minute until VO2max is reached. Capillary blood will be obtained before and immediately after the test for the blood lactate analysis. The highest value of VO2 which meets one of the following criteria will be considered as the VO2max: 1) plateau of VO2 with increasing intensity, 2) respiratory exchange ratio (RER) ≥1.05, and 3) post-exercise blood lactate exceeding 8 mmol/L.
Blood Pressure
Subjects will abstain from consuming caffeine and alcohol at least 10 hours prior to the assessment. After 10 minutes rest in the seated position, blood pressure will be measured on the right arm using a blood pressure monitor (M3 Vital Signs Monitor, EDAN). Systolic and diastolic blood pressure and mean arterial pressure will be obtained over the brachial artery region with the arm supported at the heart level using an appropriately sized cuff. Measurements will be repeated after 10 minutes and the average of two separate measurements will be recorded for the analysis.
Lean Mass
Total body lean mass will be determined by using DXA scan.
Bone Mineral Density
Bone mineral density will be determined by using DXA scan.
Fasting glucose
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of fasting glucose.
Insulin
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of insulin.
HbA1c
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of HbA1c.
Alanine aminotransferase ALT
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of ALT.
Aspartate aminotransferase AST
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of AST.
LDL cholesterol
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of LDL cholesterol.
HDL cholesterol
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of HDL cholesterol.
Total cholesterol
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of total cholesterol.
Triglycerides
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of triglycerides.
Class adherence
Class attendance will be recorded to indicate adherence to HIIT intervention. Subjects will be encouraged to achieve >70% class attendance over the year.
Dropout rate
The reasons for dropout will be ascertained and reported.
Dose-response relationship between attendance and other outcome variables
Secondary analysis will be performed based on the attendance rate to examine the dose-response relationship between HIIT and the other outcome variables.
Quality of Life measured by Short Form-12
The validated Chinese version Standard SF-12 Health Survey will be used to measure health-related quality of life. This 12-item questionnaire assesses physical functioning, emotional and mental health, bodily pain, general health, vitality and social functioning. A higher overall score indicates better quality of life.
Mental Health measured by the Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) will also be used to evaluate the severity of depression and anxiety. This 7-item questionnaire has an overall score ranging from 0 to 21 (with subscales for both anxiety and depression). A higher score indicates more severe symptoms.
Anxiety level measured by Generalized Anxiety Disorder-7 (GAD-7)
Generalized Anxiety Disorder-7 (GAD-7) will also be used to measure the anxiety level of the subjects. This 7-item questionnaire has an overall score ranging from 0 to 21. A higher score indicates more severe symptoms.
Depression level measured by Patient Health Questionnaire-9 (PHQ-9)
Patient Health Questionnaire-9 (PHQ-9) will also be used to measure the depression level of the subjects. This 10-item questionnaire has an overall score ranging from 0 to 30. A higher score indicates more severe symptoms.
Sleep Quality
Pittsburgh Sleep Quality Index (PSQI) will be used to measure the subjective sleep quality of the subjects. The score of this scale ranges from 0 to 21. Higher score indicates worse subjective sleep quality.
Adverse Events
Adverse events will be closely monitored through regular surveys by the athletics coaches and research personnel, and by voluntary reports from the subjects. The incidence rate in both usual care control group and HIIT group will be calculated as incidence rate = number of adverse events in each group / number of participants in each group.
Medication usage
The number of participants in each group using dyslipidemic and hypertensive medications will be recorded, including e.g., drug name, type, dose and weekly frequency).
Habitual Physical Activity
Habitual physical activity will be measured by International Physical Activity Questionnaire (IPAQ) and 7-day actigraph. Subjects will wear the actigraph at the hip region for 24 hours over 8 consecutive days. The first day will be a trial and not be included into the analysis.
Dietary Intake
The dietary intake will be measured by 3-day weighed food record and analyzed by Food Processor, ESHA. A food ingestion report will be generated by the software, including total calories intake, proportion of major macro nutrients.

Full Information

First Posted
April 9, 2019
Last Updated
June 20, 2022
Sponsor
The University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT03912272
Brief Title
12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
Official Title
Effectiveness of Long-term Low-frequency High-Intensity Interval Training (HIIT) to Improve Body Adiposity and Liver Fat in Adults With Central Obesity: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obesity and non-alcoholic fatty liver disease (NAFLD) are two related growing epidemics that are becoming pressing public health concerns. High-intensity interval training (HIIT) is a promising cost-effective and time-efficient exercise modality for managing obesity and NAFLD. However, patients with obesity and NAFLD are generally inactive and unfit, and might feel intimidated by the frequency of the prescribed HIIT (conventionally three times weekly). Previous HIIT studies, mostly over 2-4 month periods, showed that the participants could accomplish this exercise frequency under a controlled laboratory environment, but the long-term adherence and sustainability, especially in a field setting, remains uncertain. The situation is more unclear if we also consider those individuals who refused to participate possibly because of their overwhelming perceptions or low self-efficacy toward HIIT. Thus, logically, HIIT at a lower frequency would be practical and more suitable for patients with obesity and NAFLD, but the minimum exercise frequency required to improve health, especially in the long-term, is unknown. This proposed study aims to examine the effectiveness of long-term low-frequency HIIT for improving body adiposity and liver fat in centrally obese adults. The premise of this proposal is supported by recent findings that HIIT performed once a week could improve cardiorespiratory fitness, blood pressure, cardiac morphology, metabolic capacity, muscle power, and lean mass. This study will provide evidence for the benefits of long-term low-frequency HIIT with a follow-up period to assess its effectiveness, safety, adherence, and sustainability. We expect this intervention will enhance the practical suitability of HIIT in inactive obese adults and will provide evidence for low-frequency HIIT as a new exercise option in the management of obesity and NAFLD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Alcoholic Fatty Liver Disease, Central Obesity
Keywords
Long-Term Low-Frequency High-Intensity Interval Training, Non-Alcoholic Fatty Liver Disease, Central Obesity, Body Adiposity, Liver Fat

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Usual Care Control
Arm Type
Placebo Comparator
Arm Description
Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend >70% of the classes.
Arm Title
High-intensity Interval Training Group
Arm Type
Experimental
Arm Description
HIIT will be prescribed once weekly under the supervision of certified athletics coaches for 12 months. HIIT training will be performed in a small group setting (4-8 participants each group) in laboratories. In each session, subjects will run for four 4-minute intervals at 85%-95% of the peak heart rate (HRpeak) with a 3-minute active recovery at 50%-70% of the HRpeak between each interval. A 5-minute jog at an intensity of 70% of the HRpeak will be included for warm-up and cool-down before and after, respectively. Subjects will be asked to attend >70% of the classes.
Intervention Type
Behavioral
Intervention Name(s)
High-intensity Interval Training
Intervention Description
In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
Intervention Type
Behavioral
Intervention Name(s)
Usual Care Control
Intervention Description
In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
Primary Outcome Measure Information:
Title
Liver Fat
Description
Intrahepatic triglycerides will be examined by 1H-MR spectroscopy in a 3×3×3 cm voxel using a 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. NAFLD will be defined as >5% intrahepatic triglycerides assessed by 1H-MR spectroscopy.
Time Frame
Change from baseline amount of intrahepatic triglycerides content at 12 months
Title
Body Adiposity
Description
Total body fat mass will be determined using a full body dual-energy X-ray absorptiometry (DXA) scanner (Explorer S/N 91075, Hologic Inc., Waltham, USA). A trained technician will operate the DXA machine, position the subjects and analyze the results. The typical coefficients of variation of the DXA scanner for each body compartment from duplicate analyses are 0.4% for lean mass, 1.4% for fat mass and 1.0% for bone mass
Time Frame
Change from baseline amount of body fat mass at 12 months
Title
Liver Fat
Description
Intrahepatic triglycerides will be examined by 1H-MR spectroscopy in a 3×3×3 cm voxel using a 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. NAFLD will be defined as >5% intrahepatic triglycerides assessed by 1H-MR spectroscopy.
Time Frame
Change from baseline amount of intrahepatic triglycerides content at 24 months
Title
Body Adiposity
Description
Total body fat mass will be determined using a full body dual-energy X-ray absorptiometry (DXA) scanner (Explorer S/N 91075, Hologic Inc., Waltham, USA). A trained technician will operate the DXA machine, position the subjects and analyze the results. The typical coefficients of variation of the DXA scanner for each body compartment from duplicate analyses are 0.4% for lean mass, 1.4% for fat mass and 1.0% for bone mass
Time Frame
Change from baseline amount of body fat mass at 24 months
Secondary Outcome Measure Information:
Title
Visceral Adiposity
Description
Abdominal visceral fat will be measured using a three-point Dixon sequence using a 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. The abdominal visceral fat between the thoracic diaphragm and the upper bORDER of the first sacral vertebra will be manually marked on each MRI transverse image to calculate the volume of abdominal visceral fat.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Subcutaneous Adiposity
Description
Subcutaneous fat will be measured using a three-point Dixon sequence using 1.5-Tesla scanner (SIGNA™ Explorer - 60cm, General Electric Healthcare) housed at the MR imaging unit of HKU core facility. A trained MRI radiographer will operate the machine, position the subjects and analyze the results. The abdominal subcutaneous fat between the thoracic diaphragm and the upper border of the first sacral vertebra will be manually marked on each MRI transverse
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Body Mass Index
Description
A calibrated electronic digital weighing scale (UC321, A&D Medical) with a capacity from 0.05kg to 150kg (± 0.05kg accuracy) will be used to weigh the subjects. A stadiometer (Holtain Ltd., UK) with 200 cm limit and ± 0.01 cm accuracy will be used to measure body height. The BMI will be calculated from the body weight and height.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Waist Circumference
Description
Waist circumference will be measured on bare skin midway between the lowest rib and the superior border of the iliac crest using an inelastic measuring tape to the nearest 0.1 cm. Measurement will be performed at the end of normal expiration.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Hip Circumference
Description
Hip circumference will be be taken on bare skin around the widest portion of the buttocks using an inelastic measuring tape to the nearest 0.1 cm and the tape should be placed parallel to the floor.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
VO2max
Description
VO2max test will be conducted using a calibrated motor-driven treadmill (LE500C, Jaeger, Germany) by continuous metabolic VO2 measurement using a Cosmed K5 portable telemetric gas analysis system. The test will be performed using a ramp protocol where the speed will be constant and the incline will be increased by 2% every second minute until VO2max is reached. Capillary blood will be obtained before and immediately after the test for the blood lactate analysis. The highest value of VO2 which meets one of the following criteria will be considered as the VO2max: 1) plateau of VO2 with increasing intensity, 2) respiratory exchange ratio (RER) ≥1.05, and 3) post-exercise blood lactate exceeding 8 mmol/L.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Blood Pressure
Description
Subjects will abstain from consuming caffeine and alcohol at least 10 hours prior to the assessment. After 10 minutes rest in the seated position, blood pressure will be measured on the right arm using a blood pressure monitor (M3 Vital Signs Monitor, EDAN). Systolic and diastolic blood pressure and mean arterial pressure will be obtained over the brachial artery region with the arm supported at the heart level using an appropriately sized cuff. Measurements will be repeated after 10 minutes and the average of two separate measurements will be recorded for the analysis.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Lean Mass
Description
Total body lean mass will be determined by using DXA scan.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Bone Mineral Density
Description
Bone mineral density will be determined by using DXA scan.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Fasting glucose
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of fasting glucose.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Insulin
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of insulin.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
HbA1c
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of HbA1c.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Alanine aminotransferase ALT
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of ALT.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Aspartate aminotransferase AST
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of AST.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
LDL cholesterol
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of LDL cholesterol.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
HDL cholesterol
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of HDL cholesterol.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up.
Title
Total cholesterol
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of total cholesterol.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up.
Title
Triglycerides
Description
Subjects will fast overnight for 10 hours. Subjects will sit in a quiet environment for 15 minutes prior to blood collection. Venous blood will be drawn from an antecubital vein in the forearm by a certified phlebotomist and sent to an accredited medical laboratory to measure the level of triglycerides.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up.
Title
Class adherence
Description
Class attendance will be recorded to indicate adherence to HIIT intervention. Subjects will be encouraged to achieve >70% class attendance over the year.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Dropout rate
Description
The reasons for dropout will be ascertained and reported.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Dose-response relationship between attendance and other outcome variables
Description
Secondary analysis will be performed based on the attendance rate to examine the dose-response relationship between HIIT and the other outcome variables.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Quality of Life measured by Short Form-12
Description
The validated Chinese version Standard SF-12 Health Survey will be used to measure health-related quality of life. This 12-item questionnaire assesses physical functioning, emotional and mental health, bodily pain, general health, vitality and social functioning. A higher overall score indicates better quality of life.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Mental Health measured by the Hospital Anxiety and Depression Scale (HADS)
Description
The Hospital Anxiety and Depression Scale (HADS) will also be used to evaluate the severity of depression and anxiety. This 7-item questionnaire has an overall score ranging from 0 to 21 (with subscales for both anxiety and depression). A higher score indicates more severe symptoms.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Anxiety level measured by Generalized Anxiety Disorder-7 (GAD-7)
Description
Generalized Anxiety Disorder-7 (GAD-7) will also be used to measure the anxiety level of the subjects. This 7-item questionnaire has an overall score ranging from 0 to 21. A higher score indicates more severe symptoms.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Depression level measured by Patient Health Questionnaire-9 (PHQ-9)
Description
Patient Health Questionnaire-9 (PHQ-9) will also be used to measure the depression level of the subjects. This 10-item questionnaire has an overall score ranging from 0 to 30. A higher score indicates more severe symptoms.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Sleep Quality
Description
Pittsburgh Sleep Quality Index (PSQI) will be used to measure the subjective sleep quality of the subjects. The score of this scale ranges from 0 to 21. Higher score indicates worse subjective sleep quality.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Adverse Events
Description
Adverse events will be closely monitored through regular surveys by the athletics coaches and research personnel, and by voluntary reports from the subjects. The incidence rate in both usual care control group and HIIT group will be calculated as incidence rate = number of adverse events in each group / number of participants in each group.
Time Frame
The adverse events will be recorded during the one-year intervention period
Title
Medication usage
Description
The number of participants in each group using dyslipidemic and hypertensive medications will be recorded, including e.g., drug name, type, dose and weekly frequency).
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Habitual Physical Activity
Description
Habitual physical activity will be measured by International Physical Activity Questionnaire (IPAQ) and 7-day actigraph. Subjects will wear the actigraph at the hip region for 24 hours over 8 consecutive days. The first day will be a trial and not be included into the analysis.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up
Title
Dietary Intake
Description
The dietary intake will be measured by 3-day weighed food record and analyzed by Food Processor, ESHA. A food ingestion report will be generated by the software, including total calories intake, proportion of major macro nutrients.
Time Frame
All assessments will be repeated at 12 months post-intervention and at 24 months at the follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cantonese, Mandarin or English speaking, Aged 18-60, Central obesity, defined as BMI ≥25 (obesity classification adopted by the Hong Kong Government) with waist circumference of ≥90 cm for men and ≥80 cm for women (abdominal obesity according to the International Diabetes Federation's Chinese ethnic-specific criterion), Willing to initiate lifestyle modification but not pharmacologic or surgical means for treating obesity. Exclusion criteria: ≥150 minutes moderate-intensity exercise or ≥75 minutes vigorous exercise weekly, Regular HIIT (≥1 weekly) in the past six months, Medical history of cardiovascular disease, chronic pulmonary or kidney disease, heart failure, cancer, and liver disease except for NAFLD, Somatic conditions that limit exercise participation (e.g., limb loss), Impaired mobility due to chronic diseases (e.g., chronic arthritis/osteoarthritis, neurological, musculoskeletal and autoimmune diseases), Daily smoking habit, Excess alcohol consumption (daily ≥30 g of alcohol for men and ≥20 g for women) in the past six months Surgery, therapy or medication for obesity or weight loss in the past 6 months (e.g., gastric bypass, gastric band, sleeve gastrectomy, gastric reduction duodenal switch, and dietitian-prescribed dietary program). During the study period, subjects identified with major physical changes that would considerably affect their body composition and weight (e.g., anorexia nervosa, bulimia nervosa, and prolonged gastrointestinal and digestive disorders) will be excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Edwin Chin, PhD
Phone
28315291
Email
edwincyc@connect.hku.hk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ming Fai Parco Siu, PhD
Organizational Affiliation
Li Ka Shing Faculty of Medicine, The University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Li Ka Shing Faculty of Medicine, The University of Hong Kong
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Edwin Chin, PhD
Phone
28315291
Email
edwincyc@connect.hku.hk
Facility Name
Li Ka Shing Faculty of Medicine, The University of Hong Kong
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Edwin Chin, PhD
Email
edwincyc@connect.hku.hk

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The data of individual participants that underlie the results reported in this trial, after de-identification including text, tables, figures, and appendices, as well as study protocol and statistical analysis plan, will be shared after 3 months of study publication. Data will be shared with researchers who provide a methodologically sound proposal for academic purposes. Proposals should be directed to pmsiu@hku.hk to gain access and for data request, a data-access agreement needs to be signed.
IPD Sharing Time Frame
Beginning 3 months and ending 3 years following the publication of the article
IPD Sharing Access Criteria
Data will be shared with researchers who provide a methodologically sound proposal for academic purposes. Proposals should be directed to pmsiu@hku.hk to gain access and for data request, a data-access agreement needs to be signed.
Citations:
PubMed Identifier
23303884
Citation
Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.
Results Reference
background
PubMed Identifier
26000038
Citation
Siu PM, Yu AP, Benzie IF, Woo J. Effects of 1-year yoga on cardiovascular risk factors in middle-aged and older adults with metabolic syndrome: a randomized trial. Diabetol Metab Syndr. 2015 Apr 30;7:40. doi: 10.1186/s13098-015-0034-3. eCollection 2015.
Results Reference
background
Citation
Siu PM. Efficacy of Tai Chi training to alleviate insomnia in older adults. Proceeding of The 6th International Conference on Nutrition and Physical Activity (NAPA 2015), Taipei, Taiwan 2015;p.59
Results Reference
background
Citation
Siu PM, Yu AP, Yu DS, Hui SS, Woo J. Effectiveness of Tai Chi training to alleviate metabolic syndrome in abdominal obese older adults: A randomized controlled trial.
Results Reference
background
Citation
Siu PM, Yu AP, Yu DS, Hui SS, Woo J. Effects of Tai Chi Exercise on Cardiometabolic Health and Muscle Content. Proceeding of the 3rd Asian Conference for Frailty and Sarcopenia, Seoul, Korea 2017
Results Reference
background
PubMed Identifier
28747269
Citation
Ramos JS, Dalleck LC, Borrani F, Beetham KS, Mielke GI, Dias KA, Wallen MP, Keating SE, Fassett RG, Coombes JS. High-intensity interval training and cardiac autonomic control in individuals with metabolic syndrome: A randomised trial. Int J Cardiol. 2017 Oct 15;245:245-252. doi: 10.1016/j.ijcard.2017.07.063. Epub 2017 Jul 21.
Results Reference
background
PubMed Identifier
28846513
Citation
Ramos JS, Dalleck LC, Borrani F, Beetham KS, Wallen MP, Mallard AR, Clark B, Gomersall S, Keating SE, Fassett RG, Coombes JS. Low-Volume High-Intensity Interval Training Is Sufficient to Ameliorate the Severity of Metabolic Syndrome. Metab Syndr Relat Disord. 2017 Sep;15(7):319-328. doi: 10.1089/met.2017.0042. Epub 2017 Jun 22.
Results Reference
background
PubMed Identifier
27480182
Citation
Ramos JS, Dalleck LC, Borrani F, Mallard AR, Clark B, Keating SE, Fassett RG, Coombes JS. The effect of different volumes of high-intensity interval training on proinsulin in participants with the metabolic syndrome: a randomised trial. Diabetologia. 2016 Nov;59(11):2308-2320. doi: 10.1007/s00125-016-4064-7. Epub 2016 Aug 1.
Results Reference
background
PubMed Identifier
27467767
Citation
Ramos JS, Dalleck LC, Ramos MV, Borrani F, Roberts L, Gomersall S, Beetham KS, Dias KA, Keating SE, Fassett RG, Sharman JE, Coombes JS. 12 min/week of high-intensity interval training reduces aortic reservoir pressure in individuals with metabolic syndrome: a randomized trial. J Hypertens. 2016 Oct;34(10):1977-87. doi: 10.1097/HJH.0000000000001034.
Results Reference
background
Citation
Siu PM, Chin EC, Wong SH, Fong DY, Chan DK, Ngai HH, Lee CH, Yung PS. Low-frequency high-intensity interval training (HIIT) improves cardiorespiratory fitness and body composition in overweight adults. Med Sci Sports Exerc 2018:abstract submitted to the 65th American College of Sports Medicine (ACSM) Annual Meeting.
Results Reference
background
PubMed Identifier
35401766
Citation
Chin EC, Leung CK, Yu DJ, Yu AP, Bernal JK, Lai CW, Chan DKC, Ngai HH, Yung PSH, Lee CH, Fong DY, Keating SE, Coombes JS, Siu PM. Effects of one-year once-weekly high-intensity interval training on body adiposity and liver fat in adults with central obesity: Study protocol for a randomized controlled trial. J Exerc Sci Fit. 2022 Apr;20(2):161-171. doi: 10.1016/j.jesf.2022.03.003. Epub 2022 Mar 14.
Results Reference
derived

Learn more about this trial

12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat

We'll reach out to this number within 24 hrs